Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2×AXL bispecific ADC
- Development stage
- Preclinical
- Lead developer
- AbTis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HER2×AXL bispecific ADC is a bispecific antibody-drug conjugate (ADC) designed to simultaneously target Human Epidermal Growth Factor Receptor 2 (HER2) and AXL receptor tyrosine kinase. Developed by AbTis and Dong-A ST using the eKiH (enhanced knob-into-hole) platform, this agent aims to overcome tumor heterogeneity and resistance mechanisms, such as epithelial-mesenchymal transition (EMT), which are often driven by AXL signaling. The ADC can be conjugated with various payloads, including monomethyl auristatin E (MMAE) or exatecan (a topoisomerase-I inhibitor), and has shown preclinical efficacy in HER2-expressing solid tumors like lung, breast, and gastric cancers, particularly those refractory to standard therapies.
- Other names
- HER2xAXL BsAbHER-2xAXL BsAbHER 2xAXL BsAb
02
Targets
AXL (AXL receptor tyrosine kinase)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB2 (Erb-b2 receptor tyrosine kinase 2)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on HER2×AXL bispecific ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2×AXL bispecific ADC.